In this context, it was demonstrated that insulator elements shield heterologous promoters from non-specific transactivation by adenoviral enhancers. Other studies are being undertaken to facilitate viral dissemination throughout the tumor. Integrating adeno-AAV hybrid vectors for sickle cell gene therapy. Dr. Lieber has developed a novel, integrating DAd. AAV hybrid vector devoid of all viral genes that combines features of adenoviral vectors including high titer, high infectivity, and large capacity with the integration capability of AAV ITRs.
Ongoing studies focus on the improvement of integration frequency of DAd.
AAV vectors and on the stimulation of site-specific integration by incorporating the AAV Rep function into hybrid vectors. Dr Lieber has developed a strategy to specifically retarget adenoviruses to any cell type of interest. This approach involves creating a library of adenoviruses displaying random peptides in their fiber knobs as ligands and screening this library for adenovirus variants with tropism to a particular cell type in vitro and potentially in vivo. All rights reserved.